共 50 条
- [1] Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) trial - E4599LUNG CANCER, 2005, 49 : S31 - S31Sandler, ABGray, RBrahmer, JDowlati, ASchiller, JHPerry, MCJohnson, DH
- [2] Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell Lung CancerJOURNAL OF THORACIC ONCOLOGY, 2010, 5 (09) : 1416 - 1423Sandler, AlanYi, JingDahlberg, SuzanneKolb, Margaret M.Wang, LisaHambleton, JulieSchiller, JoanJohnson, David H.
- [3] Efficacy and safety of paclitaxel and carboplatin with bevacizumab for the first-line treatment of patients with nonsquamous non-small cell lung cancer (NSCLC): Analyses based on age in the phase III PointBreak and E4599 trialsJOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)Langer, Corey J.Socinski, Mark A.Patel, Jyoti D.Sandler, AlanSchiller, Joan H.Leon, LarryUttamsingh, ShailajaRamalingam, Suresh S.
- [4] A phase II trial of weekly paclitaxel and carboplatin for elderly patients with advanced non-small cell lung cancer (NSCLC).JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 682S - 682SUsui, KInoue, AIshimoto, OTanaka, MKoinumaru, SMatsubara, NKanbe, MGomi, KSaijo, YNukiwa, T
- [5] Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial-E4599JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 1090S - 1090SSandler, ABGray, RBrahmer, JDowlati, ASchiller, JHPerry, MCJohnson, DH
- [6] Clinical course of advanced non-small cell lung cancer (NSCLC) patients (pts) experiencing hypertension (HTN) during treatment (TX) with bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P) on E4599JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)Dahlberg, S. E.Sandler, A. B.Brahmer, J. R.Schiller, J. H.Johnson, D. H.
- [7] EFFICACY AND SAFETY OF PACLITAXEL AND CARBOPLATIN WITH BEVACIZUMAB FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH NONSQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC): ANALYSES BASED ON AGE IN THE PHASE 3 POINTBREAK AND E4599 TRIALSJOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S291 - S292Langer, Corey J.Socinski, Mark A.Patel, Jyoti D.Sandler, Allan B.Schiller, Joan H.Leon, LarryHazard, SebastienRamalingam, Suresh S.
- [8] Randomized Phase II Study of Paclitaxel and Carboplatin or Vinorelbine in Advanced Non-small Cell Lung CancerANTICANCER RESEARCH, 2011, 31 (01) : 317 - 323Jahnke, KristophKeilholz, UlrichLueftner, DianaThiel, EckhardSchmittel, Alexander
- [9] A randomized phase III trial comparing bexarotene/carboplatin/paclitaxel versus carboplatin/paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC).JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 1094S - 1094SBlumenschein, GRKhuri, FGatzemeier, UMiller, WHvon Pawel, JRigas, JRHerbst, RSDziewanowska, ZNegro-Vilar, AMabry, M
- [10] A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): SWOG S0819JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S795 - S795Herbst, RoyRedman, MaryKim, Edward S.Semrad, Thomas J.Bazhenova, LyudmilaMasters, GregoryOettel, KurtGuaglianone, PerryReynolds, ChristopherKarnad, AnandArnold, Susanne M.Varella-Garcia, MarileilaMoon, JamesMack, Philip C.Blanke, Charles D.Hirsch, Fred R.Gandara, David R.